TIRZEPATIDE 10mg

Tirzepatide – Dual GIP/GLP-1 Receptor Agonist for Metabolic & Weight Management Research

Tirzepatide is a novel dual-incretin receptor agonist, targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is currently being studied for its potential to significantly enhance insulin sensitivity, reduce appetite, and support weight loss and glycaemic control in metabolic research models.

By activating both GIP and GLP-1 pathways, Tirzepatide offers a synergistic effect that has shown promising results in early research related to type 2 diabetes, obesity, and metabolic syndrome, making it one of the most cutting-edge peptides in current metabolic and endocrinological studies.

Key Research Highlights:

• Dual-agonist targeting GIP and GLP-1 receptors

• Studied for significant weight reduction and appetite control

• Investigated for improving insulin sensitivity and glucose regulation

• Long-acting profile suitable for weekly administration in research models

• Non-insulin, non-stimulant mechanism of action

For research purposes only. Not for human or veterinary use.
This product is not intended to treat, prevent, mitigate, or cure any disease or medical condition. It is strictly for research use and should not be used in humans, animals, or diagnostic procedures. Researchers must be at least eighteen (18) years of age to purchase this product.

Important Note:
Bacteriostatic Water is recommended for reconstitution of Tirzepatide. Diluent is not included and must be purchased separately. If not added to your cart at checkout, it will not be provided.